Skip to main content

Table 1 Patient characteristics

From: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

 No. (%) of Patients
Age (yr)
 Median80
 Range75–87
Sex
 Male19 (63.3)
 Female11 (36.7)
Karnofsky performance status
 100, 902 (6.7)
 80, 7017 (56.7)
 60, 5011 (36.7)
Extent of resection
 Total resection8 (26.7)
 Subtotal resection3 (10)
 Partial resection7 (23.3)
 Biopsy12 (40)
Chemotherapy
 Temozolomide20 (66.7)
 Temozolomide/Bevacizumab10 (33.3)
Adjuvant Temozolomide cycles (n)
 Median5
 Range0–20
Use of corticosteroid
 Yes6 (20)
 No24 (80)
Treatment after tumor recurrence
 Best supportive care21 (70)
 Bev5 (16.7)
 Surgery followed by Temozolomide1 (3.3)
 Temozolomide1 (3.3)
 No recurrence2 (6.7)
MGMT promoter status
 High11 (36.7)
 Low16 (53.3)
 N/A3 (10)
IDH 1/2 status
 Wild-type29 (96.7)
 Mutant0
 N/A1 (3.3)
  1. IDH Isocitrate dehydrogenase, MGMT O6-methylguanine DNA methyltransferase, N/A Not available